Date: 19/02/2025, Ahmedabad
Vaishali Pharma Ltd., a leading pharmaceutical company with a strong global presence, has acquired a 51% majority stake in Kesar Pharma Ltd by primary infusion. This strategic acquisition is set to enhance Vaishali Pharma’s market position, expand its manufacturing capabilities, and strengthen its supply chain through backward integration.
Strategic Rationale and Benefits
The acquisition aligns with Vaishali Pharma’s long-term growth strategy by adding Kesar Pharma’s well-established manufacturing facilities to its portfolio. By leveraging Kesar Pharma’s infrastructure and expertise, Vaishali Pharma will achieve enhanced production efficiency, cost optimization, and increased market penetration. This move will also ensure the full utilization of Kesar Pharma’ s existing resources, maximizing productivity and profitability.
With this acquisition, Vaishali Pharma gains a manufacturing facility that complies with WHO-GMP and other international regulatory guidelines. Notably, Kesar Pharma’s manufacturing facilities are approved by leading regulatory authorities in countries such as Nigeria, Kenya, Uganda, Congo, Ghana, Madagascar, Rwanda, Angola, Uzbekistan, Kyrgyzstan, Myanmar, the Philippines, and Cambodia. This approval underscores the high standards maintained by Kesar Pharma and further strengthens Vaishali Pharma’s global credibility.
Through this acquisition, Vaishali Pharma is eyeing a turnover of 300 crore in the next two years.
Advisory Partner
The acquisition was facilitated by Abans Financial Services Ltd. (Formerly Known as Abans Holdings Ltd), which provided strategic advisory services.
